Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 20/20 | 1.00 |
| ▸ | JAK2 | O60674 | 13/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25410279 | 1.00 | JAK1 (1.00) | JAK1JAK2 | |
| SCHEMBL18662691 | 1.00 | JAK1 (1.00) | JAK1JAK2 | |
| SCHEMBL18662627 | 0.95 | JAK1 (1.00) | JAK1JAK2 | |
| SCHEMBL25406444 | 0.95 | JAK1 (1.00) | JAK1JAK2 | |
| SCHEMBL29392629 | 0.95 | JAK1 (1.00) | JAK1JAK2 | |
| SCHEMBL25410426 | 0.95 | JAK1 (1.00) | JAK1JAK2 | |
| SCHEMBL18662677 | 0.95 | JAK1 (1.00) | JAK1JAK2 | |
| SCHEMBL25409701 | 0.94 | JAK1 (1.00) | JAK1JAK2 | |
| SCHEMBL18662628 | 0.94 | JAK1 (1.00) | JAK1JAK2 | |
| SCHEMBL29394755 | 0.94 | JAK1 (1.00) | JAK1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3353168-B1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2023-08-30 | — | — | EP | claimed |
| US-12319670-B2 | Compounds and methods for inhibiting JAK | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2025-06-03 | — | — | US | disclosed |
| US-20220119372-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2022-04-21 | — | — | US | disclosed |
| US-11247983-B2 | Compounds and methods for inhibiting JAK | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12319670-B2 | Compounds and methods for inhibiting JAK | JAK2, JAK3, JAK1 | JAK1 3/4885JAK2 1/4885 |
| US-20220119372-A1 | COMPOUNDS AND METHODS FOR INHIBITING JAK | JAK2, JAK3, JAK1 | JAK1 3/4885JAK2 1/4885 |
| US-11247983-B2 | Compounds and methods for inhibiting JAK | JAK2, JAK3, JAK1 | JAK1 3/4885JAK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.